$87.52
Near FV▼ -3.8% against the close used
Model range $34.74 – $153.25
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear$34.74Fair value$87.52Bull$153.25
FairClose
52-week traded range
52W low $73.7552W high $105.35
The 52-week range is measured from the stored price history, not estimated.
Trading close to the consensus fair value
Medtronic closed at $90.96, 3.9% above the consensus fair value of $87.52 drawn from 9 valuation models.
Financial DNA score 66/100 — Strong. P/E of 24.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
$83.68
-8.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
$57.24
-37.1%
√(22.5 × EPS × BVPS)
EPS=3.73, BVPS=39.04 · outside Graham range (P/E 24.4, P/B 2.3) — asset-light, treat as a rough floor
P/E Fair Value
$74.60
-18.0%
EPS × 20x (sector P/E)
EPS=3.73, Sector P/E=20x
Peter Lynch (PEG)
$88.33
-2.9%
EPS × Growth% (PEG = 1 is fair)
EPS=3.73, g=23.7%
EV/EBITDA
$131.80
+44.9%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=9.43B
Dividend Discount (DDM)
$153.25
+68.5%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=2.84, r=10%, g=8%
Book Value (P/B)
$34.74
-61.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=39.04, ROE=9.6%, g=6%, r=10%
Reverse DCF
$90.96
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 9.8% | Historical: 23.7%
Margin of Safety
$53.88
-40.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=71.84, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.